Shield Therapeutics has successfully secured significant funding for the development of ST10 and PT20, with capital coming from the founders; private individuals and financial investors. With a highly-skilled, experienced and focused team operating in Switzerland and the UK, the company’s central mission is to deliver exceptional value to the patients and prescribers who use our products, as well as the payors who reimburse their use, to the ultimate benefit of our shareholders and staff.

If you would like to find out more about investment opportunities with Shield Therapeutics please contact us.

“We are excited by the opportunity to work together with the dynamic and experienced team of Shield”

-Dr Gunnar Weikart, CEO of Inventages